𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma

✍ Scribed by Vuoristo, Merisisko; Jantunen, Ismo; Pyrhönen, Seppo; Muhonen, Timo; Kellokumpu-Lehtinen, Pirkko

Book ID
123411734
Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
410 KB
Volume
30
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunotherapy of advanced renal cell can
Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-α
✍ H. Kirchner; W. Riese; E. Allhoff; H. Poliwoda; J. Atzpodien 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 450 KB

The combined administration of subcutaneous recombinant human interleukin-2 (rIL-2) and interferon-a (rIFN-~) was studied in a phase II trial on patients with advanced progressive renal cell cancer. Safety, tolerance and clinical response rate of this outpatient treatment protocol were assessed in 2

Sequential treatment of patients with ad
Sequential treatment of patients with advanced renal cell carcinoma with autologous tumor vaccine and subcutaneous administration of recombinant interleukin-2 and interferon α2b
✍ S. Pomer; R. Thiele; V. Daniel; R. Weimer; H. Löhrke; V. Schirrmacher; G. Staehl 📂 Article 📅 1991 🏛 Springer-Verlag 🌐 English ⚖ 820 KB

Thirty patients with advanced renal cell carcinoma (RCC), 23 of whom had distant metastases in at least one organ, were entered after nephrectomy into a protocol involving vaccination with Newcastle disease virus (NDV)-modified autologous tumour material, with a subsequent induction week and repetit